CDK4/6 Inhibitor Market Snapshot: New Drugs Jockey For A Piece Of The Multi-Billion Dollar Pie
Executive Summary
Pfizer's Ibrance has a strong lead in the CDK4/6 space, but Novartis' Kisqali and Lilly's Verzenio are looking to carve out their own niches, expand the category and move into earlier treatment settings. Another scramble is on as well, to answer the question: what comes next?
You may also be interested in...
Pfizer Ibrance Hopes Dashed In Early-Stage Breast Cancer
Data from the PENELOPE-B study in high-risk early breast cancer patients show no separation from placebo, compounding the earlier failure of the PALLAS trial in low- and high-risk patients.
EQRx Reveals Two New Assets For Low-Cost Drug Pipeline
The start-up launched in January with $200m to develop lower-priced drugs against known targets. Now it has licensed a CDK4/6 inhibitor from G1 Therapeutics and an EGFR inhibitor from Hansoh.
Oncology Market Leaders Maintain Their Upper Hand
Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.